Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Patent
1995-06-07
1996-12-17
Feisee, Lila
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
5303873, 53038822, 4241431, C07K 1618, A61K 39395
Patent
active
055850898
ABSTRACT:
Novel methods for producing, and compositions of humanized immunoglobulins having one or more complementarity determining regions (CDR's) and possible additional amino acids from a donor immunoglobulin and a framework region from an accepting human immunoglobulin are provided. Each humanized immunoglobulin chain will usually comprise, in addition to the CDR's, amino acids from the donor immunoglobulin framework that are, e.g., capable of interacting with the CDR's to effect binding affinity, such as one or more amino acids which are immediately adjacent to a CDR in the donor immunoglobulin or those within about 3 .ANG. as predicted by molecular modeling. The heavy and light chains may each be designed by using any one or all of various position criteria. When combined into an intact antibody, the humanized immunoglobulins of the present invention will be substantially non-immunogenic in humans and retain substantially the same affinity as the donor immunoglobulin to the antigen, such as a protein or other compound containing an epitope.
REFERENCES:
patent: 4578335 (1986-03-01), Urdal et al.
patent: 4816397 (1989-03-01), Boss et al.
patent: 4816565 (1989-03-01), Honjo et al.
patent: 4816567 (1989-03-01), Cabilly et al.
patent: 4845198 (1989-07-01), Urdal et al.
patent: 4867973 (1989-09-01), Goers et al.
patent: 5198359 (1993-03-01), Taniguchi et al.
patent: 5225539 (1993-07-01), Winter
Riechmann et al. Nature vol. 332 24, Mar. 1988 p. 323.
Foote, Nova Acta Leopoldina 1989. vol. 61 (269) 103.
Amit et al. Science vol. 233 1986 p. 747.
Groves et al. vol. 6, 1987, p. 71.
Better et al., "Escherichia coli Secretion of an Active Chimeric Antibody Fragment", Science 240:1041-1043 (1988).
Bird et al., "Single-Chain Antigen-Binding Proteins", Science 242:423-426 (1988).
Boulianne et al., "Production of functional chimeric mouse/human antibody," Nature 312:643-646 (1984).
Carter et al., "Humanization of an anti-p185.sup.HER2 antibody for human cancer therapy," Proc. Natl. Acad. Sci. 89:4285-4289 (1992).
Chothia, C. and A. M. Lesk, "Canonical Structures for the Hypervariable Regions of Immunoglobulins", J. Mol. Biol. 196:901-917 (1987).
Co et al., "Humanized antibodies for antiviral therapy," Proc. Natl. Acad. Sci. USA 88:2869-2873 (1991).
Co et al., "Chimeric and Humanized Antibodies with Specificity for the CD33 Antigen," J. of Immunol. 148(4):1149-1154 (1992).
Daugherty et al., "Polymerase chain reaction facilitates the cloning, CDR-grafting, and rapid expression of a murine monoclonal antibody directed against the CD18 component of leukocyte integrins," Nuc. Acids Res. 19:2471-2476 (1991).
Ellison et al., "The nucleotide sequence of a human immunoglobulin C(gamma).sub.1 gene", Nucleic Acids Res. 10:4071-(1982).
Farrar, J., "The biochemistry, biology, and role of interleukin-2 in the induction of cytotoxic T cell and antibody-forming B cell receptors," Immunol. Rev. 63:129-166 (1982).
Foote et al., "Antibody framework residues affecting the conformation of hypervariable loops," J. Mol. Biol. 224:487-499 (1992).
Gorman et al., "Reshaping a therapeutic CD4 antibody," Proc. Natl. Acad. Sci. 88:4181-4185 (1991).
Greene et al., "Growth of Human T Lymphocytes: An Analysis of Interleukin 2 and Its Cellular receptor", in Progress in Hematology XIV, E. Brown, ed., Grune and Statton, New York (1986) pp. 283-301.
Hale et al., "Remission Induction in Non-Hodgkin Lymphoma with Reshaped Human Monoclonal Antibody CAMPATH-1H", Lancet Dec. 17, 1988, pp. 1394-1399.
Hieter et al., "Cloned Human and Mouse Kappa Immunoglobulin Constant and J Region Genes Conserve Homology in Functional Segments", Cell 22:197-207 (1980).
Huston et al., "Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli", Proc. Natl. Acad. Sci. U.S.A. 85:5879-5883 (1988). in Progress in Hematology XIV, E. Brown, ed., Grune and Statton, New York (1986) p. 283.
Jones et al., "Replacing the complementarity-determining regions in a human antibody with those from a mouse", Nature 321:522-525 (1986).
Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," Protein Engineering 4:773-783 (1991).
Kirkman et al., Journal of Expt. Med. vol. 162:358 Jul. 1985.
Leonard et al., "The human receptor for T-cell growth factor," J. Biol. Chem. 260:1872-1880 (1985).
Liu et al., "Expression of mouse::human immunoglobulin heavy-chain cDNA in lymphoid cells", Gene 54:33-40 (1987).
Maeda et al., "Construction of reshaped human antibodies with HIV-neutralizing activity", Hum. Antibod. Hybrid. 2:124-134 (1991).
Morrison et al., "Chimeric human antibody molecules: Mouse antigen-binding domains with human constant region domains," Proc. Natl. Acad. Sci. 81:6851-6859 (1984).
Morrison, S. L., "Transfectomas Provide Novel Chimeric Antibodies," Science 229:1202-1207 (1985).
Neuberger et al., "A hapten-specific chimeric IgE antibody with human physiological effector function," Nature 314:268-270 (1985).
Queen et al., "A humanized antibody that binds to the interleukin 2 receptor," Proc. Natl. Acad. Sci. USA 86:10029-10033 (1989).
Riechmann et al., "Reshaping human antibodies for therapy", Nature 332:323-327 (1988).
Routledge et al., "A humanized monovalent CD3 antibody which can activate homologous complement," Eur. J. Immunol. 21: 2717-2725 (1991).
Sahagan et al., "A Genetically Engineered Murine/Human Chimeric Antibody Retains Specificity for Human Tumor-Associated Antigen", J. Immunol. 137:1066-1074 (1986).
Shalaby et al., "Development of humanized bispecific antibodies reactive with cytotoxic lymphocytes and tumor cells overexpressing the HER2 protooncogene," J. Exp. Med. 175:217-225 (1992).
Sharon et al., "Expression of a V.sub.H C.sub.K chimaeric protein in mouse myeloma cells", Nature 309:364-367 (1984).
Shearman et al., "Construction, expression and characterization of humanized antibodies directed against the human .alpha./.beta. T cell receptor," J. Immunol. 147(12):4366-4373 (1991).
Takeda et al., "Construction of chimaeric processed immunoglobulin genes containing mouse variable and human constant region sequences", Nature 314:452-454 (1985).
Tan et al., "A Human-Mouse Chimeric Immunoglobulin Gene with a Human Variable Region is Expressed in Mouse Myeloma Cells", J. Immunol. 135:3564-3567 (1985).
Tempest et al., "Reshaping a human monoclonal antibody to inhibit human respiratory syncytial virus infection in vivo," Bio/Technology 9:226-271 (1991).
Uchiyama et al., "A monoclonal antibody (anti-Tac) reactive with activated and functionally mature human T-cells," J. Immunol. 126:1393-1397 (1981).
Verhoeyen et al., "Reshaping Human Antibodies: Grafting an Antilysozyme Activity", Science 239:1534-1536 (1988).
Vitteta et al., "Redesigning Nature's Poisons to Create Anti-Tumor Reagents," Science 238:1098-1104 (1987).
Waldmann, T. A., "The Structure, Function, and Expression of Interleukin-2 Receptors on Normal and Malignant Lymphocytes," Science 232:727-732 (1986).
Woodle et al., "Humanized OKT3 antibodies: successful transfer of immune modulating properties and idiotype expression," J. Immunol. 148:2756-2763 (1992).
Junghans et al., Cancer Res., 50:1495-1502 (1990).
Kupiec-Weglinski et al., Proc. Natl. Acad. Sci., 83:2624 (1986).
Queen Cary L.
Selick Harold E.
Feisee Lila
Protein Design Labs, Inc.
LandOfFree
Humanized immunoglobulins does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Humanized immunoglobulins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Humanized immunoglobulins will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1989245